Previous studies have demonstrated a synergistic killing effect of combined EGFR and PARP blockade in cancer cells 52, and our data also suggest that combination therapy with EGFR and PARP inhibitors has the potential to be an effective therapeutic strategy for multiple tumours beyond hereditary BRCA1- and BRCA2-deficient tumours. This evidence concerns the gene BRCA2 and neoplasm.